-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Zhitong Finance App, Yingpai Pharmaceutical-B (07630.HK) announced that the innovative drug Senapali (Chinese product name: Pai Shuning®, overseas product name: Sepalna®) has officially obtained a final decision from the European Commission (EC) and approved for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The approval was made by the European Commission (EC) based on positive opinions from the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP). Since then, senapalil has become the first first-line maintenance PARP inhibitor for advanced ovarian cancer in China to be approved and marketed by the European Union, marking another breakthrough for domestically produced innovative drugs targeting ovarian cancer in the European market.

智通財經·11/16/2026 22:25:25
語音播報
According to Zhitong Finance App, Yingpai Pharmaceutical-B (07630.HK) announced that the innovative drug Senapali (Chinese product name: Pai Shuning®, overseas product name: Sepalna®) has officially obtained a final decision from the European Commission (EC) and approved for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The approval was made by the European Commission (EC) based on positive opinions from the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP). Since then, senapalil has become the first first-line maintenance PARP inhibitor for advanced ovarian cancer in China to be approved and marketed by the European Union, marking another breakthrough for domestically produced innovative drugs targeting ovarian cancer in the European market.